当前位置:首页 - 行情中心 - 瑞普生物(300119) - 财务分析 - 现金流量表

瑞普生物

(300119)

  

流通市值:72.52亿  总市值:100.62亿
流通股本:3.35亿   总股本:4.65亿

现金流量表

报告期2025-06-302025-03-312024-12-312024-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,657,858,383.59756,952,689.893,170,360,885.841,735,389,701.38
  收到的税费返还4,220,572.791,980,813.613,607,563.481,987,660.73
  收到其他与经营活动有关的现金272,922,537.46231,607,476.43921,883,442.1940,796,835.87
  经营活动现金流入小计1,935,001,493.84990,540,979.934,095,851,891.511,778,174,197.98
  购买商品、接受劳务支付的现金946,628,817.79422,719,182.251,581,089,886.03723,794,832.49
  支付给职工以及为职工支付的现金270,042,876.03139,240,951.96498,737,623.44345,313,404.12
  支付的各项税费87,225,175.7540,056,770.55162,583,806.47108,876,053.87
  支付其他与经营活动有关的现金495,730,932.31314,992,935.031,117,894,368.42244,066,349.78
  经营活动现金流出小计1,799,627,801.88917,009,839.793,360,305,684.361,422,050,640.26
  经营活动产生的现金流量净额135,373,691.9673,531,140.14735,546,207.15356,123,557.72
二、投资活动产生的现金流量:
  收回投资收到的现金1,034,452,256.34655,498,6323,460,801,3672,548,098,367
  取得投资收益收到的现金41,496,641.225,114,275.8438,268,958.6618,709,881.27
  处置固定资产、无形资产和其他长期资产收回的现金净额83,13133,02363,837.9155,449.91
  收到的其他与投资活动有关的现金34,902.9834,902.9837,585,388.8937,585,388.89
  投资活动现金流入小计1,076,066,931.54660,680,833.823,536,719,552.462,604,449,087.07
  购建固定资产、无形资产和其他长期资产支付的现金89,215,614.8463,271,205.52185,337,088.6145,259,807.69
  投资支付的现金868,723,000692,223,0003,562,174,2502,486,890,000
  取得子公司及其他营业单位支付的现金117,000,000-240,005,230.65202,650,230.65
  支付其他与投资活动有关的现金--876,652.78876,652.78
  投资活动现金流出小计1,074,938,614.84755,494,205.523,988,393,222.032,835,676,691.12
  投资活动产生的现金流量净额1,128,316.7-94,813,371.7-451,673,669.57-231,227,604.05
三、筹资活动产生的现金流量:
  吸收投资收到的现金6,600,0006,600,00027,200,000-
  其中:子公司吸收少数股东投资收到的现金6,600,0006,600,00020,000,000-
  取得借款收到的现金761,980,000172,930,0801,028,502,502698,050,000
  收到其他与筹资活动有关的现金6,361,779.3985,171,302.4117,519,750.2515,000,000
  筹资活动现金流入小计774,941,779.39264,701,382.411,073,222,252.25713,050,000
  偿还债务支付的现金518,698,605.8109,667,000535,579,230289,333,280
  分配股利、利润或偿付利息支付的现金183,903,151.7232,303,999.75263,122,582.32241,578,621.49
  其中:子公司支付给少数股东的股利、利润32,405,091.5124,880,092.1847,338,773.8734,994,773.87
  支付其他与筹资活动有关的现金152,348,249.17127,194,519.36407,798,961.59292,536,102.56
  筹资活动现金流出小计854,950,006.69269,165,519.111,206,500,773.91823,448,004.05
  筹资活动产生的现金流量净额-80,008,227.3-4,464,136.7-133,278,521.66-110,398,004.05
四、汇率变动对现金及现金等价物的影响172,814.38163,359.08664,007.64392,159.94
五、现金及现金等价物净增加额56,666,595.74-25,583,009.18151,258,023.5614,890,109.56
  加:期初现金及现金等价物余额476,225,863.54476,225,863.54324,967,839.98321,529,914.7
  期末现金及现金等价物余额532,892,459.28450,642,854.36476,225,863.54336,420,024.26
补充资料:
  净利润272,063,586.89-329,833,903.18-
  资产减值准备20,375,065.29-39,305,540.96-
  固定资产和投资性房地产折旧83,233,560.73-151,525,864.71-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧83,233,560.73-151,525,864.71-
  无形资产摊销24,924,978.59-42,507,520.66-
  长期待摊费用摊销240,992.86-750,024.8-
  处置固定资产、无形资产和其他长期资产的损失-3,729,955.17-16,698.12-
  固定资产报废损失203,060.76-143,459.09-
  公允价值变动损失-43,282,384.88-10,707,752.8-
  财务费用18,553,122.22-32,772,007.09-
  投资损失-32,094,818.1--9,142,829.12-
  递延所得税2,959,919.61-409,835.96-
  其中:递延所得税资产减少-2,974,736.61--10,716,441.08-
    递延所得税负债增加5,934,656.22-11,126,277.04-
  存货的减少-32,408,121.07--22,631,740.31-
  经营性应收项目的减少-98,978,935.63--75,822,169.93-
  经营性应付项目的增加-82,408,634.92-228,964,276.78-
  其他3,345.25--4,678,265.2-
  现金的期末余额532,892,459.28-476,225,863.54-
  减:现金的期初余额476,225,863.54-324,967,839.98-
  现金及现金等价物的净增加额56,666,595.74-151,258,023.56-
公告日期2025-08-262025-04-262025-04-032024-10-30
审计意见(境内)标准无保留意见
TOP↑